Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation

Inclusion Criteria: * Male or female subjects 18-75 years of age. * Subjects who are recipients of HLA-identical living donor renal allografts from a sibling and are at least 1 year post transplant, their donors and mothers. * Subjects must be capable of understanding the purpose and risks of the study and must sign a statement of informed consent. Exclusion Criteria: * GFR \<40ml/min; * diagnosis of SLE, * Subjects with proteinuria (defined as a protein:creatinine ratio of \>1 or an amount less than this deemed significant on an individual subject basis by the principal investigator),, * multi-organ transplant; * known hypersensitivity to, Prograf, Neoral, CellCept or Myfortic; * history of documented post transplant non-compliance with medications, transplant clinic or laboratory follow-up; * therapy with an investigational immunosuppressive drug within 6 weeks of study entry; * history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study; * patients on less than 500 mg PO BID of CellCept or 360 mg PO BID of Myfortic at the time of potential randomization, * history of humoral rejection post transplant, * maintenance or for cause treatment with steroids (prednisone) within 3 months of enrollment.